FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial. PMID 40737559 · Br J Dermatol · 2025-Nov-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up). PMID 40581082 · Br J Dermatol · 2025-Nov-18 The record describes a Phase IIIb/IV randomized trial of upadacitinib for atopic dermatitis, which is a non-oncology condition. The primary efficacy endpoint is a categorical response (EASI 90) and does not involve time-to-event analysis (e.g., OS, PFS, KM curves). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Strategies to improve healthcare team communication structure and quality in resource-variable childhood cancer hospitals (TeamTalk): a study protocol. PMID 41250257 · Implement Sci Commun · 2025-Nov-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Restarting anticoagulation early versus late in patients with chronic subdural hematoma and atrial fibrillation (RELACS): a phase III international multicenter, randomized controlled, two-arm, assessor-blinded trial. PMID 41250110 · Trials · 2025-Nov-17 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design. PMID 41249955 · BMC Cancer · 2025-Nov-17 The record is a clinical trial protocol for a randomized study in oncology patients, but it is not a report of formal results from a Phase III or Phase II/III trial. The primary endpoint is venous thromboembolism incidence, which is not a standard oncology efficacy endpoint (e.g., OS, PFS, DFS). No trial results, Kaplan-Meier data, or Hazard Ratios for oncology efficacy are provided. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adherence of published randomised Phase 3 cancer trials to principles proposed by common-sense oncology. PMID 41046634 · Eur J Cancer · 2025-Nov-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial. PMID 41045691 · Eur J Cancer · 2025-Nov-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial. PMID 40992225 · Eur J Cancer · 2025-Nov-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV. PMID 40924496 · J Clin Invest · 2025-Nov-17 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients. PMID 40397037 · Am J Hypertens · 2025-Nov-17 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A qualitative study of Emotion and Symptom-focused Engagement (EASE): An integrated psychotherapeutic and early palliative care intervention for patients with acute leukemia. PMID 41240159 · Support Care Cancer · 2025-Nov-15 The record describes a qualitative study protocol for a psychotherapeutic intervention within a phase III RCT for acute leukemia. It is not a report of original formal results with a drug-containing intervention and a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Enhanced recovery after surgery protocol does not reduce the length of postoperative hospitalization after robot-assisted radical prostatectomy. Outcomes from the first randomized controlled trial: the (PROSTA-RAAC) study. PMID 41240114 · World J Urol · 2025-Nov-15 The study is a randomized controlled trial in oncology (prostate cancer), but it evaluates a non-drug intervention (Enhanced Recovery after Surgery protocol) and does not have a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary endpoint is length of hospitalization, a continuous outcome, and secondary endpoints include mobilization time and quality of life, not time-to-event measures. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects and safety of traditional Chinese medicine approaches in cancer symptom care: A systematic review of phase 3 randomized clinical trials. PMID 41217297 · Cancer · 2025-Nov-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. PMID 40673336 · Int J Cancer · 2025-Nov-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Prospective Phase 2 Clinical Trial of Carbon Ion Radiation Therapy Combined With Chemotherapy for Locally Advanced Pancreatic Carcinoma. PMID 40614787 · Int J Radiat Oncol Biol Phys · 2025-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated Preoperative Radiation Therapy for Extremity and Superficial Trunk Soft Tissue Sarcomas: Results of a Prospective, Phase 2 Trial. PMID 40389098 · Int J Radiat Oncol Biol Phys · 2025-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial. PMID 41239458 · Arthritis Res Ther · 2025-Nov-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of sarcopenia on paclitaxel-induced peripheral neuropathy in early-stage breast cancer: a prospective observational study (the neuro-sarc study). PMID 41238950 · Support Care Cancer · 2025-Nov-14 The study is an observational investigation of sarcopenia and paclitaxel-induced peripheral neuropathy in early-stage breast cancer. It is not a randomized controlled trial, lacks a definitive Phase III/IIIb or Phase II/III designation, and does not have a primary time-to-event efficacy endpoint as defined (e.g., OS, PFS). The primary outcome is a toxicity incidence, making it a secondary/safety analysis. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial. PMID 41238556 · Sci Rep · 2025-Nov-14 The study meets most inclusion criteria (oncology, human, randomized, drug intervention, time-to-event endpoint with HR, original result) but the trial phase is not explicitly stated in the provided metadata. The criteria require explicit confirmation of Phase III/IIIb or Phase II/III status, which is absent. Therefore, the record is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine. PMID 41092804 · Vaccine · 2025-Nov-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial. PMID 41072276 · Vaccine · 2025-Nov-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer-The neoMono Trial. PMID 40932365 · Clin Cancer Res · 2025-Nov-14 The study is a phase II randomized trial with a drug intervention (atezolizumab) and reports primary efficacy results (pCR rates). It is excluded because it is not a phase III/IIIb or phase II/III trial as required, and it does not have a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint is pathologic complete remission (pCR), a binary outcome, not a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial. PMID 40882625 · Med · 2025-Nov-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Update on Disease-Modifying Pharmacological Treatments for Frontotemporal Dementia (FTD): A Scoping Review of Registered Trials. PMID 41283303 · NeuroSci · 2025-Nov-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme. PMID 41248393 · BMJ Open · 2025-Nov-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A scoping review of thresholds for responder and time-to-event analysis of patient-reported outcomes in breast cancer trials. PMID 41230561 · Br J Clin Pharmacol · 2025-Nov-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. PMID 40888716 · N Engl J Med · 2025-Nov-13 The study is a randomized, Phase IV clinical trial with a primary time-to-event endpoint (composite of death or major adverse cardiovascular events) and a drug intervention (beta-blockers). However, it is excluded because it is not an oncology study, focusing on cardiovascular disease (myocardial infarction) rather than human malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of argon-helium cryoablation combined with PD-1 inhibitors in non-small cell lung cancer. PMID 41229194 · Acta Oncol · 2025-Nov-12 The record describes a randomized, open-label trial in oncology patients with drug intervention (PD-1 inhibitors) and reports time-to-event efficacy endpoints (OS, PFS). However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided abstract or metadata; the deterministic review flagged phase evidence as unclear. Additionally, the intervention combines a drug (PD-1 inhibitor) with a non-drug procedure (argon-helium cryoablation), which may not fit the strict 'drug-containing intervention' criterion for a pharmacological comparison. Therefore, it is excluded due to insufficient evidence for the required trial phase and potential non-drug-only intervention component. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A randomised controlled trial comparing epinephrine and dexamethasone to placebo in the treatment of infants with bronchiolitis (BIPED study): a statistical analysis plan. PMID 41225556 · Trials · 2025-Nov-12 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021). PMID 41225446 · BMC Cancer · 2025-Nov-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Integrating narrative therapy and sleep intervention to enhance recovery, nutritional reconstitution, and 24-month survival following curative gastrectomy: a randomized controlled trial. PMID 41225165 · J Cancer Surviv · 2025-Nov-12 Study is an original oncology RCT with time-to-event endpoints but does not meet the required drug intervention criterion; phase is also not established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An open-label, randomized study comparing lipegfilgrastim with filgrastim in pediatric patients receiving chemotherapy for Ewing sarcoma or rhabdomyosarcoma. PMID 41224871 · Sci Rep · 2025-Nov-12 The study is a randomized trial in oncology patients with a drug intervention, but the phase is not specified (no explicit mention of Phase III/IIIb or II/III). The primary endpoint is duration of neutropenia (a hematologic toxicity measure), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier analysis. Therefore, it does not meet the inclusion criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| EXPRESSION OF CONCERN: Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial. PMID 41224475 · BMJ · 2025-Nov-12 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of low-molecular-weight heparin or rivaroxaban combined with immunotherapy and chemotherapy in the treatment of advanced nonsmall cell lung cancer: a prospective, randomized, controlled clinical study. PMID 41222736 · Cancer Immunol Immunother · 2025-Nov-12 The record describes a randomized, controlled trial with a drug intervention and a primary time-to-event endpoint (PFS) in human oncology. However, the trial phase is not explicitly stated in the metadata (title, abstract, publication types, or MeSH terms). Eligibility requires explicit confirmation of Phase III/IIIb or Phase II/III status. Without this, the 'phase3_or_definitive' criterion cannot be established as true, rendering the record ineligible for inclusion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Development of the rationale of a personalized cancer vaccine based on the in situ vaccine effect of radiotherapy: a mechanistic study of the POLARSTAR trial. PMID 41222702 · Cancer Immunol Immunother · 2025-Nov-12 The report is an original randomized controlled trial in oncology (rectal cancer) with a drug intervention (PD-1 blockade). However, it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier curves or hazard ratios. The primary efficacy endpoint reported is tumor response rate, which is not a time-to-event outcome. The study also includes extensive preclinical/mechanistic components (cell lines, mouse models). Therefore, it does not meet the core eligibility criterion of having a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Outcome measures for randomised clinical trials and multicentre observational studies of cardiovascular diseases published in major clinical journals: systematic review and evidence mapping. PMID 40533147 · Heart · 2025-Nov-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of Multidisciplinary Team-Based Refined Nursing on Outcomes in Elderly Patients with Liver Cirrhosis and Upper Gastrointestinal Bleeding. PMID 41325392 · J Vis Exp · 2025-Nov-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of Slow Versus Rapid Advancement of Enteral Feeding on Intestinal Oxygenation in Preterm Infants. PMID 41300644 · Children (Basel) · 2025-Nov-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of intravenous lidocaine infusion on postoperative pulmonary complications in patients undergoing minimally invasive esophagectomy: a study protocol of double-center, double-blind, randomized controlled trial. PMID 41219803 · Trials · 2025-Nov-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: a systematic review of monoclonal antibodies and fusion proteins in combination strategies. PMID 41217554 · Clin Exp Med · 2025-Nov-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Bariatric metabolic surgery and cancer risk: Target trial emulation using iterative time distribution matching. PMID 41217501 · Biomol Biomed · 2025-Nov-11 The study is an observational retrospective cohort study using target trial emulation methodology, not a randomized controlled trial. The intervention is bariatric metabolic surgery, which is a surgical procedure, not a drug-containing intervention. The study is not in a Phase III/IIIb or Phase II/III randomized trial framework. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial. PMID 41213939 · Signal Transduct Target Ther · 2025-Nov-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Narrative therapy and resilience training improve recovery and survival after intersphincteric resection for low rectal cancer: a randomized trial. PMID 41191913 · Oncologist · 2025-Nov-11 The trial is a randomized, oncology study with a time-to-event endpoint (DFS/OS) and is the original report. However, the intervention is a psychosocial program (narrative therapy and resilience training), not a drug-containing intervention as required by the cohort definition. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial. PMID 41071964 · Neurology · 2025-Nov-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer. PMID 41014160 · Oncologist · 2025-Nov-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. PMID 40720747 · Blood Adv · 2025-Nov-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of PD-1 inhibitors combined with anti-angiogenic agents in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. PMID 41258596 · Discov Oncol · 2025-Nov-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Lycopene intake and prostate cancer risk in men at high cardiovascular risk: a prospective cohort study. PMID 41214650 · BMC Med · 2025-Nov-10 The study is excluded because the intervention is dietary (lycopene intake), not a drug-containing intervention. Additionally, while it is a randomized trial (PREDIMED), this specific analysis is a prospective cohort study within that trial, and the endpoint is cancer incidence as a preventive measure, not a primary/key secondary time-to-event efficacy endpoint for a drug in a definitive oncology trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of an exercise program on chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer individuals receiving taxanes: a randomized controlled trial. PMID 41212417 · Support Care Cancer · 2025-Nov-10 The study is a randomized controlled trial in oncology with a drug intervention, but it does not include a time-to-event efficacy endpoint (e.g., OS, PFS). It evaluates a non-drug intervention for managing chemotherapy side effects and quality of life, which falls outside the required scope. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol. PMID 41213710 · BMJ Open · 2025-Nov-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |